Reviewed by Michael Gill, B. Sc.
25 Waldenstrom Macroglobulinemia Clinical Trials Near Me
Top Hospitals for Waldenstrom Macroglobulinemia Clinical Trials
Image of Dana Farber Cancer Institute in Massachusetts.
Dana Farber Cancer Institute
7Active Trials
15All Time Trials for Waldenstrom Macroglobulinemia
2011First Waldenstrom Macroglobulinemia Trial
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
5Active Trials
11All Time Trials for Waldenstrom Macroglobulinemia
2005First Waldenstrom Macroglobulinemia Trial
Top Cities for Waldenstrom Macroglobulinemia Clinical Trials
Waldenstrom Macroglobulinemia Clinical Trials by Phase of Trial
Phase < 1 Waldenstrom Macroglobulinemia Clinical Trials
1Active Waldenstrom Macroglobulinemia Clinical Trials
1Number of Unique Treatments
0Number of Active Locations
Waldenstrom Macroglobulinemia Clinical Trials by Age Group
18+ Waldenstrom Macroglobulinemia Clinical Trials
61Active Waldenstrom Macroglobulinemia Clinical Trials
Top Treatments for Waldenstrom Macroglobulinemia Clinical Trials
Treatment Name
Active Waldenstrom Macroglobulinemia Clinical Trials
All Time Trials for Waldenstrom Macroglobulinemia
First Recorded Waldenstrom Macroglobulinemia Trial
Allogeneic Hematopoietic Stem Cell Transplantation
CLBR001 and SWI019
Total Body Irradiation
Recently Completed Studies with FDA Approved Treatments for Waldenstrom Macroglobulinemia
X4 Pharmaceuticals
Celldex Therapeutics
TG Therapeutics, Inc.
Dana-Farber Cancer Institute
Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Masonic Cancer Center, University of Minnesota
PI3K inhibitor BKM120
Kami Maddocks, MD

What Are Waldenstrom Macroglobulinemia Clinical Trials?

Waldenstrom Macroglobulinemia (WM) is a rare cancer type. This cancer targets the white blood cells. The condition increases the production of abnormal WBCs in the bloodstream crowding the healthy blood cells. A protein is produced by abnormal cells which accumulate in the blood. The condition further impairs circulation and leads to complications.

Waldenstrom Macroglobulinemia (WM) is characterized as Non-Hodgkin’s lymphoma type. It is also referred to as Lymphoplasmacytic Lymphoma. It is a progressive and slow-growing condition. Some symptoms include easy bruising, fatigue, fever, weight loss, numb feet and hands, bleeding of the gums and nose, shortness of breath, and vision change.

Waldenstrom Macroglobulinemia clinical trials are studies conducted to find effective treatments to improve the quality of lives of the patients and their comfort.  

Why Is Waldenstrom Macroglobulinemia Being Studied Through Clinical Trials?

Statistics show that annually approximately 1000 to nearly 1500 individuals are reported to suffer from Waldenstrom Macroglobulinemia in the US. The occurrence of Waldenstrom Macroglobulinemia is about 3 cases/per million individuals yearly in America. Moreover, the condition is more commonly found in men. It affects white people more than African Americans.

Waldenstrom Macroglobulinemia clinical trials are being conducted for multiple reasons, such as:

  • Find ways to prevent the condition, reduce symptoms, and also side-effects.
  • Determine the best drug combinations
  • Identify targeted therapies
  • How to treat it the best
  • How to care for the patients diagnosed with Waldenstrom Macroglobulinemia

What Are the Types of Treatments Available for Waldenstrom Macroglobulinemia?

There is no specific treatment for Waldenstrom Macroglobulinemia. For cancer care, a multidisciplinary team of doctors works cohesively to create a treatment plan for every patient. Treatment options depend on factors like cancer stage, type, patient’s health, and preference. The treatment plan includes procedures like plasma exchange, chemotherapy, therapies with medication, stem cell transplantation, and targeted therapy.

What Are Some Recent Breakthrough Clinical Trials for Waldenstrom Macroglobulinemia?

2013: Novel Treatment Options for Waldenström’s Macroglobulinemia- The study focused on multiple WM treatment options like proteasome inhibitors and Immunomodulatory drugs. It concluded that new agents used for treatment offer improved response and lower long-term toxicities. However, more research must be carried out to understand the disease biology for improved outcomes.

2021: Waldenstrom Macroglobulinemia with Peripheral Neuropathy- The research was conducted on two patients with Waldenstrom Macroglobulinemia and peripheral nerve symptoms. The first patient was administered Rituximab, Dexamethasone, and Cyclophosphamide. The second patient was treated using Bendamustine and Rituximab. The first case completed remission for nine years but experienced recurrence in the tenth year, while the second completed treatment successfully over three years.

Who Are Some Key Opinion Leaders/Researchers/Institutions Conducting Waldenstrom Macroglobulinemia Clinical Trial Research?

Dana-Farber Cancer Institute

It is a highly specialized cancer care center that exclusively provides Waldenstrom diagnosis, treatment plans, and therapies through ongoing clinical research.


International Waldenstrom Macroglobulinemia Foundation is a non-profit organization that supports knowledge advancement about WM through quality research and clinical trials.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9:CD013365. doi: 10.1002/14651858.CD013365.pub2. Review. Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536. Review. Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan 15;83(2):435-45. Hong WX, Sagiv-Barfi I, Czerwinski DK, Sallets A, Levy R. Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. Cancer Res. 2022 Apr 1;82(7):1396-1408. doi: 10.1158/0008-5472.CAN-21-1382. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006 Dec 1;24(34):5343-9. Epub 2006 Nov 6. Mooney KL, Czerwinski DK, Shree T, Frank MJ, Haebe S, Martin BA, Testa S, Levy R, Long SR. Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy. Cancer Cytopathol. 2022 Mar;130(3):231-237. doi: 10.1002/cncy.22531. Epub 2021 Nov 15. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000 Sep;18(17):3135-43. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984-92.